Mortality in cancer patients with a history of cutaneous squamous cell carcinoma - a nationwide population-based cohort study

Sigrun Alba Johannesdottir1*, Timothy L Lash1, Annette Østergaard Jensen1, Dóra Körmendiné Farkas1 and Anne Braae Olesen1,2

Abstract

Background: Cutaneous squamous cell carcinoma (SCC) is associated with underlying immunosuppression, so it may be a prognostic marker in patients with subsequent cancer. We therefore conducted a nationwide population-based Danish cohort study to evaluate whether a history of cutaneous SCC has prognostic impact in patients with one of the following index cancers: non-Hodgkin’s lymphoma (NHL), or cancer of the lung, colon, rectum, breast, or prostate.

Methods: We used Danish medical databases, which cover the entire Danish population of 5.6 million inhabitants and linked them using the unique personal identification number assigned to all Danish residents. From 1982 through 2003, we identified 745 index cancer patients with and 79,143 without previous cutaneous SCC. Using Cox proportional hazards regression, we calculated adjusted mortality rate ratios (MRRs) with 95% confidence intervals (CIs).

Results: Overall, previous SCC was associated with an increased mortality of cancer (MRR 1.13, 95% CI: 1.04-1.23). When examining index cancers separately, increased MRRs were found for cancer of the lung (MRR 1.23, 95% CI: 1.05-1.43), colon (MRR 1.13, 95% CI: 0.92-1.40), rectum (MRR 1.29, 95% CI: 1.00-1.67), breast (MRR 1.09, 95% CI: 0.82-1.43), and NHL (MRR 1.09, 95% CI: 0.81-1.47), but not for prostate cancer (MRR 0.99, 95% CI: 0.83-1.18).

Conclusions: Our results suggest that previous cutaneous SCC is associated with poor prognosis of some cancers. This finding stresses the importance of adherence to the existing recommendations of screening, diagnosis, and treatment of cancer in patients with a history of SCC.

Background

Non-melanoma skin cancer (NMSC)—basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) [1]—is associated with an increased risk of developing both subsequent NMSC [2] and other malignancies compared with the general population [3-5]. Common risk factors have been proposed as the cause, for example, ultraviolet radiation (UVR) and immune incompetence [6,7]. In particular, cutaneous SCC is known to be associated with immunosuppression [6,8,9], but whether it is a reliable marker for reduced immune competence that could explain these findings is unknown. Overall, five studies have found higher mortality rates in cancer patients with previous SCC [4,10-13], which also could be explained by reduced immune competence. None of the studies, however, included information on important factors such as cancer treatments and comorbidity. Therefore, taking these factors into account, while focusing on the most common types of cancers, we conducted a nationwide population-based Danish cohort study to examine whether a history of cutaneous SCC has prognostic impact in patients with a subsequent diagnosis of one of the following index cancers: non-Hodgkin’s lymphoma (NHL), or cancer of the lung, colon, rectum, breast, or prostate.
Methods
The current study was conducted using Danish medical databases, which cover the entire Danish population of 5.6 million inhabitants [14]. Accurate and unambiguous linkage of all registries was possible using the unique personal identification number assigned to all Danish residents [14].

Study cohort
From the Danish Cancer Registry (DCR), we identified all patients aged 20 to 99 years with a first diagnosis of an index cancer from 1982 through 2003 occurring in the month after a cutaneous SCC diagnosis or later. Because of the rarity of a history of SCC of the skin among cancer patients, we chose to focus on the most common types of cancer (cancer of the lung, colon, rectum, breast, or prostate). In addition, we included NHL because of its link to immune function and for comparison with previous studies on the topic [4,10-13]. The DCR contains records of all incident malignant neoplasms in Denmark since 1943 and provides details on morphology, histology, stage of cancer at the time of diagnosis, and initial cancer therapies within four months of diagnosis [15]. All diagnostic codes used in this study are provided in the Additional file 1: Table S1.

Given abundant data in the DCR, in combination with the fact that our focus was mortality following the most common cancers in Denmark, we decided that for each selected cancer patient with a history of cutaneous SCC, we would randomly choose 100 patients with the same index cancer but without preceding SCC of the skin.

Initially, we aimed to include human immunodeficiency virus (HIV) diagnosis and previous solid organ transplantation as a measure of immune function, but due to a small numbers of patients in these categories, we excluded all patients with HIV (n = 4) or previous solid organ transplantation (n = 45). Due to a small numbers of patients with a history of cutaneous SCC in age groups 20-29 years (n = 0), 30-39 years (n = 1) and 40-49 years (n = 3), we chose not to include these age groups in the analysis.

Mortality data
We identified all-cause death using the Danish Civil Registration System (established on April 2, 1968), which is updated daily and records all changes in vital status, date of death, and migration [14]. We identified cancer-specific death using the Danish Registry of Causes of Death, which contains information on all deaths in Denmark since 1943 [16]. We used the cause of death reported on the death certificate grouped into 14 categories as defined by the National Board of Health [17]. Each death certificate includes one underlying, and up to three immediate causes of death [16]. If any of these causes were a malignancy, we used that as the cause of death.

Comorbidity
We obtained information on comorbid diseases from The Danish National Patient Registry, which provides information about all inpatient admissions to somatic hospitals since 1977, and all outpatient and emergency admissions since 1995 [18]. We categorized the level of comorbidity by using the Charlson Comorbidity Index (CCI) [19], an extensively studied and validated instrument used to predict risk of death from comorbid diseases [19,20]. We computed the CCI score for each study subject based on the complete hospital discharge history for at least 5 years before index cancer diagnosis, and grouped it into three levels: Low = 0, medium = 1-2, and high > 3.

According to our hypothesis cutaneous SCC is associated with poor prognosis in cancer patients due to underlying immune incompetence. We would therefore expect diseases involving the immune system or immunosuppressive therapies to be more frequent in patients with a history of SCC. To examine this, we also included a list of autoimmune diseases, as a proxy measure of immune function.

Statistical analysis
To include information on initial cancer therapies, follow-up started four months after index cancer diagnosis, and continued until death, emigration, diagnosis of cutaneous SCC in patients without that history at diagnosis of the index cancer, end of follow-up (31 December 2008), or a maximum of 10 years, whichever came first. 130 patients who had died or were censored by start of follow-up were not included in the analysis.

Initially, we computed the frequency and proportion of covariates, number of deaths and amount of accumulated person-time within index cancer cohorts, stratified by history of cutaneous SCC. Then, we calculated crude mortality rate ratios (MRRs) with 95% confidence intervals (CIs) associating previous cutaneous SCC with mortality.

We used Cox proportional hazard regression to estimate MRRs with 95% CIs for index cancer patients with a history of cutaneous SCC compared with index cancer patients without such history adjusting for age group (50-69, 70-79, 80-89, 90-99 years), a variable that calculated the endpoint of the age group divided by exact age for each individual, gender, CCI (low, medium, high), calendar period (1982-1986, 1987-1991, 1992-1996, 1997-2001, 2002-2003), history of autoimmune disease...
without a history of cutaneous SCC. Patients with previous cutaneous SCC were older at index cancer diagnosis, were more frequently men, had their index cancer diagnosis in a more recent calendar period, and had higher comorbidity (Table 1). Furthermore, SCC patients had more frequently missing stage and treatment information, more often received no or symptomatic treatment (except in breast cancer) and had more frequently a history of any autoimmune disease (see Additional file 2: Table S2).

**Mortality**

We observed shorter survival time among those with a history of cutaneous SCC within all index cancer groups, with an overall median survival time of 1.93 years (lower quartile 0.58 years; upper quartile 5.09 years) in SCC patients and 2.57 years (lower quartile 0.74 years; upper quartile 6.54 years) in patients without SCC (Additional file 2: Table S2). The most frequent cause of death was malignancy. We were not able to distinguish between NMSC subtypes for cause of death, but a total of 22 persons died of NMSC (2.95% of deaths) among the exposed and 31 (0.04% of deaths) among the unexposed patients.

Overall, a history of cutaneous SCC was associated with an increased relative rate of death from cancer (MRR 1.13, 95% CI: 1.04-1.23) (Table 2). When examining index cancers separately, increased MRRs were found for cancer of the lung (MRR 1.23, 95% CI: 1.05-1.43), colon (MRR 1.13, 95% CI: 0.92-1.40), rectum (MRR 1.29, 95% CI: 1.00-1.67), breast (MRR 1.09, 95% CI: 0.82-1.43), and NHL (MRR 1.09, 95% CI: 0.81-1.47). There was no increased rate of dying of prostate cancer (MRR 0.97, 95% CI: 0.81-1.15).

The impact of covariates on the mortality rate of cancer is shown in Table 3. The stratified analysis revealed no effect modification (data not shown).

**Impact of prognostic factors**

After including all other covariates, adding comorbidity to the model resulted in a 7% attenuation of the MRR for NHL, but had no effect in the remaining cancers. Adjusting for stage did not affect the results, while adjusting for cancer treatment had an impact in lung and breast cancer in the sense that it raised their MRRs by approximately 7%.

Increasing the enrollment period to 2008 resulted in no substantial change for prostate (MRR 1.03, 95% CI: 0.88-1.21) and colon cancer (MRR 1.10, 95% CI: 0.90-1.33), while an increase was observed for rectal cancer (MRR 1.43, 95% CI: 1.13-1.81) and NHL (MRR 1.23, 95% CI: 0.96-1.57).

**Discussion**

We found that a history of cutaneous SCC was associated with a moderately increased mortality rate
following a diagnosis of cancer of the lung, colon, rectum, breast, and NHL, but not in survivors of prostate cancer. The present study is the first to examine this association taking into account comorbidity and index cancer treatments. Adjustment for these factors had no substantial effect on our results, so it is unlikely that they have introduced major confounding in previous studies.

Table 1 Selected characteristics of persons diagnosed with an index cancer (cancer of the lung, colon, rectum, breast, prostate, or non-Hodgkin’s lymphoma (NHL)) in Denmark 1982-2003, by history of cutaneous squamous cell carcinoma (SCC)

| Characteristics | Lung cancer | | | Colon cancer | | | Rectal cancer | | |
|-----------------|-------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
|                  | + SCC (%)   | - SCC (%)       | + SCC (%)       | - SCC (%)       | + SCC (%)       | - SCC (%)       | + SCC (%)       | - SCC (%)       | + SCC (%)       | - SCC (%)       |
| Total            | 175         | 18,662          | 138             | 14,647          | 77              | 7,089           |
| Gender           |             |                 |                 |                 |                 |                 |                 |                 |
| Men              | 140 (80)    | 11,673 (63)     | 87 (63)         | 6,592 (45)      | 60 (78)         | 4,086 (58)      |
| Women            | 35 (20)     | 6,989 (37)      | 51 (37)         | 8,055 (55)      | 17 (22)         | 3,003 (42)      |
| Age group (years) |             |                 |                 |                 |                 |                 |                 |                 |
| 50-69            | 49 (28)     | 11,471 (61)     | 23 (17)         | 5,968 (41)      | 15 (19)         | 3,383 (48)      |
| 70-79            | 82 (47)     | 5,895 (32)      | 48 (35)         | 5,479 (37)      | 34 (44)         | 2,487 (35)      |
| 80-89            | 41 (23)     | 1,241 (6.7)     | 59 (43)         | 2,958 (20)      | 22 (29)         | 1,107 (16)      |
| 90-99            | 3 (1.7)     | 55 (0.3)        | 8 (5.8)         | 242 (1.7)       | 6 (7.8)         | 112 (1.6)       |
| Calendar period  |             |                 |                 |                 |                 |                 |                 |                 |
| 1982-1986        | 19 (11)     | 3,798 (20)      | 12 (8.7)        | 3,023 (21)      | 11 (14)         | 1,565 (22)      |
| 1987-1991        | 25 (14)     | 3,866 (21)      | 26 (19)         | 3,219 (22)      | 15 (19)         | 1,557 (22)      |
| 1992-1996        | 47 (27)     | 4,101 (22)      | 35 (25)         | 3,324 (23)      | 22 (29)         | 1,578 (22)      |
| 1997-2001        | 66 (38)     | 4,832 (26)      | 49 (36)         | 3,549 (24)      | 17 (22)         | 1,683 (24)      |
| 2002-2003        | 18 (10)     | 2,065 (11)      | 16 (12)         | 1,532 (10)      | 12 (16)         | 706 (10)        |
| Comorbidity level|             |                 |                 |                 |                 |                 |                 |                 |
| Low              | 81 (46)     | 12,081 (65)     | 81 (59)         | 10,806 (74)     | 54 (70)         | 5,477 (77)      |
| Moderate         | 69 (39)     | 5,306 (28)      | 47 (34)         | 3,221 (22)      | 18 (23)         | 1,365 (19)      |
| High             | 25 (14)     | 1,275 (6.8)     | 10 (7.3)        | 620 (4.2)       | 5 (6.5)         | 247 (3.5)       |
| Breast cancer    |             |                 |                 |                 |                 |                 |                 |
|                  | + SCC (%)   | - SCC (%)       | + SCC (%)       | - SCC (%)       | + SCC (%)       | - SCC (%)       | + SCC (%)       | - SCC (%)       |
| Total            | 113         | 10,418          | 186             | 21,364          | 56              | 6,963           |
| Gender           |             |                 |                 |                 |                 |                 |                 |                 |
| Men              | -           | 186 (100)       | 21,364 (100)    | 46 (82)         | 3,896 (56)      |
| Women            | 113 (100)   | 10,418 (100)    | -               | -              | 10 (18)         | 3,067 (44)      |
| Age group (years) |             |                 |                 |                 |                 |                 |                 |                 |
| 50-69            | 25 (22)     | 6,298 (60)      | 18 (9.7)        | 7,014 (33)      | 11 (20)         | 3,253 (47)      |
| 70-79            | 38 (34)     | 2,569 (25)      | 83 (45)         | 9,423 (44)      | 21 (38)         | 2,492 (36)      |
| 80-89            | 40 (35)     | 1,369 (13)      | 77 (41)         | 4,61 (22)       | 20 (36)         | 1,130 (16)      |
| 90-99            | 10 (8.9)    | 182 (1.8)       | 8 (4.3)         | 308 (1.4)       | 4 (7.1)         | 88 (1.3)        |
| Calendar period  |             |                 |                 |                 |                 |                 |                 |                 |
| 1982-1986        | 6 (5.3)     | 1,866 (18)      | 20 (11)         | 3,825 (18)      | 8 (14)          | 1,261 (18)      |
| 1987-1991        | 18 (16)     | 2,029 (19)      | 30 (16)         | 4,562 (21)      | 10 (18)         | 1,392 (20)      |
| 1992-1996        | 28 (25)     | 2,469 (24)      | 39 (21)         | 4,333 (20)      | 13 (23)         | 1,659 (24)      |
| 1997-2001        | 44 (39)     | 2,806 (27)      | 69 (37)         | 5,700 (27)      | 15 (27)         | 1,876 (27)      |
| 2002-2003        | 17 (15)     | 1,248 (12)      | 28 (15)         | 2,944 (14)      | 10 (18)         | 775 (11)        |
| Comorbidity level|             |                 |                 |                 |                 |                 |                 |                 |
| Low              | 77 (68)     | 8,406 (81)      | 106 (57)        | 14,554 (68)     | 28 (50)         | 5,183 (74)      |
| Moderate         | 29 (26)     | 1,667 (16)      | 58 (31)         | 5,558 (26)      | 20 (36)         | 1,517 (22)      |
| High             | 7 (6.2)     | 345 (3.3)       | 22 (12)         | 1,252 (5.9)     | 8 (14)          | 263 (3.8)       |

*aAge at index cancer diagnosis

*bCalendar period of index cancer diagnosis

*cThree levels of comorbidity were defined based on Charlson index scores of 0 (low), 1-2 (medium), and > 2 (high)

*dIncludes the phenotypic variant chronic lymphocytic leukemia
were lower for BCC than SCC patients. This reduced immune function may be interesting since UVR induces cellular immune incompetence [6]. This reduced immune function may be observed both locally and systemically and it is more pronounced in patients with previous skin cancer than in the general population [6,21]. We therefore hypothesize that cutaneous SCC is a marker of underlying immunosuppression that compromises the patient’s normal immune surveillance against nascent tumor cells resulting in poor prognosis of subsequent cancer. NHL is interesting from this immunologic perspective, given its strong association with immune function. Hence, we would have expected a greater increase compared with the other cancers that are not as strongly related to immune function. However, the imprecision of our estimates, especially for NHL, limit us from concluding on any substantial differences between cancers. Furthermore, alternative explanations such as field cancerization due to an unidentified carcinogen may also explain our findings.

The low number of observations limited the analysis of associations for subtypes of autoimmune diseases,
and since the degree of immunosuppression varies with severity and type of autoimmune disease “a history of any autoimmune disease” may be an imperfect reflection of immunosuppression. Furthermore, information on a history of autoimmune disease may be underreported, especially in the mild cases. These limitations prevent us from ruling out a differential effect in people with autoimmune disease.

Our study has several limitations. Even though the Danish Cancer Registry is close to complete for most malignancies [15], NMSC registration is probably underreported [5,22] due to the high incidence of NMSCs burdening the systems and the high cure rate that may cause clinicians to consider it trivial, especially in patients with comorbidity [23]. We do not, however, find it likely that mortality of a malignancy occurring later in time would affect misclassification of cutaneous SCC.

Misclassification of cause of death may be possible. The Danish Registry of Causes of Death has varying validity for different causes of death, although it is almost complete for cancer deaths [16,24,25]. The major problem with the registry is that the sequence of events may not be accurate [25]. To avoid this problem, we considered cause of death to be cancer if any cause on the death certificate was a malignancy. Moreover, we repeated all analyses for all-cause death by using the civil registration system, which is virtually complete [14]. This change in outcome slightly attenuated the results, but they were not substantially different from the cancer-specific MRRs.

Surveillance bias might have affected our results if preceding SCC of the skin is associated with increased medical surveillance leading to earlier diagnosis, and hence, better prognosis. This bias would have worked against the direction of the observed association, so it cannot explain the results. In addition, a Danish study of NMSC and risk of subsequent cancer found no evidence of more intensive surveillance for internal malignancies [5], which is in accordance with Danish guidelines on follow-up in patients with cutaneous SCC [26]. Moreover, we found no substantial difference between mortality rates stratified on time between SCC and index cancer diagnoses.

Conclusions
The present study is the first to examine mortality in cancer patients with previous SCC of the skin, taking comorbidity and cancer treatments into account. Previous studies have found an increased risk of cancer in SCC patients [3-5] and our study extends this to also include an increased mortality of some types of cancer. Given the increasing incidence of cutaneous SCC [1], these results stress the importance of adherence to the existing recommendations of screening, diagnosis, and treatment of cancer in patients with a history of cutaneous SCC.

Additional material

Additional file 1: International Classification of Diseases (ICD) codes used in the study. A table presenting all ICD codes used in the study.

Additional file 2: Table with distribution of additional characteristics. A table presenting the distribution of autoimmune diseases, stage, treatment, and the median, lower and upper quartile for the survival time in the cohort.

Acknowledgements
Special thanks to professor Henrik Toft Sørensen for formulating the study idea. The study received financial support from the Aarhus University Research Foundation; the Danish Medical Research Council; Danish Agency of Science, Technology and Innovation; the Agnes and Poul Frits Fund, the Copenhagen University Fund for medical students; the Manufacturer Einar Willumsens Memorial Award; the Else and Mogens Wedell-Wedellsborgs Fund; Civil Engineer Bent Bagh and Wife Inge Baghs Fund; the Andersen-Isted fund; and Frits, Georg and Marie Cecilia Gluds Foundation.

Authors’ contributions
SAJ, TLL, AØJ, and ABO made substantial contributions to the conception and design of the study. DKF performed the acquisition of data. SAJ conducted the analysis of the data. All authors contributed to the interpretation of data, drafting and revising the manuscript, and have given final approval of the version to be published.

Competing interests
The authors declare that they have no competing interests.

Received: 10 November 2011 Accepted: 29 March 2012

Published: 29 March 2012

References
1. Madan V, Lear JT, Szemies RM: Non-melanoma skin cancer. Lancet 2010, 375:675-685.
2. Marcil I, Stern RS: Risk of developing a subsequent nonmelanoma skin cancer in patients with a history of nonmelanoma skin cancer: a critical review of the literature and meta-analysis. Arch Dermatol 2000, 136:1524-1530.
3. Waxberg C, Thörn M, Yuen J, Ringborg U, Hakulinen T: Second primary cancers in patients with squamous cell carcinoma of the skin: a population-based study in Sweden. Int J Cancer 1999, 80:511-515.
4. Nugent Z, Demers AA, Wiseman MC, Mihalciou C, Kiewer EV: Risk of second primary cancer and death following a diagnosis of nonmelanoma skin cancer. Cancer Epidemiol Biomarkers Prev 2005, 14:2584-2590.
5. Frisch M, Melbye M: New primary cancers after squamous cell skin cancer. Am J Epidemiol 1995, 141:916-922.
6. Ulrich SE: Mechanisms underlying UV-induced immune suppression. Mutat Res 2005, 571:185-205.
7. Adamu J, Frisch M, Yuen J, Glimelius B, Melbye M: Evidence of an association between non-Hodgkin’s lymphoma and skin cancer. BMJ 1995, 310:1491-1495.
8. Dendukuri N, Erhler WB: Aging biology and cancer. Semin Oncol 2004, 31:137-148.
9. Oberszyn TM: Non-melanoma skin cancer: Importance of gender, immunosuppressive status and vitamin D. Cancer Lett 2008, 261:127-136.
10. Askling J, Sørensen P, Ekborn A, Frisch M, Melbye M, Glimelius B, Hjalgrim H: Is history of squamous-cell skin cancer a marker of poor prognosis in patients with cancer? Ann Intern Med 1999, 131:655-659.

11. Hjalgrim H, Frisch M, Storm HH, Glimelius B, Pedersen JB, Melbye M: Non-melanoma skin cancer may be a marker of poor prognosis in patients with non-Hodgkin's lymphoma, Int J Cancer 2000, 85:639-642.

12. Kahn HS, Tatham LM, Patel AV, Thun MJ, Heath CW: Increased cancer mortality following a history of nonmelanoma skin cancer. JAMA 1998, 280:910-922.

13. Toro JR, Blake PW, Bjorkholm M, Kristinsson SY, Wang Z, Landgren O: Prior history of non-melanoma skin cancer is associated with increased mortality in patients with chronic lymphocytic leukemia. Haematologica 2009, 94:1460-1464.

14. Pedersen CB, Gøtzsche H, Møller JO, Mortensen PB: The Danish civil registration system. a cohort of eight million persons. Dan Med Bull 2006, 53:441-449.

15. Storm HH, Michelsen EV, Clemmensen IH, Pihl J: The Danish cancer registry - history, content, quality and use. Dan Med Bull 1997, 44:535-539.

16. Juel K, Helweg-Larsen K: The Danish registers of causes of death. Dan Med Bull 1999, 46:354-357.

17. The National Board of Health. Grouping of Causes of Death. [http://www.sst.dk].

18. Andersen TF, Madsen M, Jørgensen J, Møller JO, Mortensen PB: The Danish civil registration system. a cohort of eight million persons. Dan Med Bull 2006, 53:441-449.

19. Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40:373-383.

20. Needham DM, Scales DC, Laupacis A, Pronovost PJ: A systematic review of the Charlson comorbidity index using Canadian administrative databases: a perspective on risk adjustment in critical care research. J Crit Care 2005, 2012-19.

21. Schwarz T: The Dark and the Sunny Sides of UVR-Induced Immunosuppression: Photoimmunology Revisited. J Invest Dermatol 2009, 130:49-54.

22. Jerven AB, Olesen AB, Dethlefsen C, Sorensen HT: Do incident and new subsequent cases of non-melanoma skin cancer registered in a Danish prospective cohort study have different 10-year mortality? Cancer Detect Prev 2007, 31:352-358.

23. Green A, Trichopoulos D: Skin Cancer. In Textbook of cancer epidemiology. Edited by: Adams HO, Hunter DJ, Trichopoulos D. New York: Oxford University Press; 2002:281-300.

24. Juel K: Registration of cause of death in Denmark. Ugeskr Laeger 1998, 160:5019.

25. Mabeck CE, Wichmann B: Causes of death and death certificates: Assessment of the diagnoses in 373 death certificates. Ugeskr Laeger 1980, 142:257-261.

26. Guidelines from the Danish Dermatological Society. [http://www.dds.nu].

Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2407/12/126/prepub

doi:10.1186/1471-2407-12-126
Cite this article as: Johannesdottir et al.: Mortality in cancer patients with a history of cutaneous squamous cell carcinoma - a nationwide population-based cohort study. BMC Cancer 2012 12:126.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit